Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Leases (2022 - 2025)

Caribou Biosciences has reported Current Leases over the past 4 years, most recently at $1.2 million for Q4 2025.

  • Quarterly Current Leases fell 15.78% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 15.78% year-over-year, with the annual reading at $1.2 million for FY2025, 15.78% down from the prior year.
  • Current Leases was $1.2 million for Q4 2025 at Caribou Biosciences, down from $2.7 million in the prior quarter.
  • Over five years, Current Leases peaked at $2.7 million in Q3 2025 and troughed at $825000.0 in Q1 2022.
  • The 4-year median for Current Leases is $1.2 million (2023), against an average of $1.3 million.
  • The largest YoY upside for Current Leases was 128.1% in 2025 against a maximum downside of 15.78% in 2025.
  • A 4-year view of Current Leases shows it stood at $966000.0 in 2022, then grew by 24.22% to $1.2 million in 2023, then rose by 18.83% to $1.4 million in 2024, then fell by 15.78% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Current Leases are $1.2 million (Q4 2025), $2.7 million (Q3 2025), and $2.3 million (Q2 2025).